Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

LumiraDx Limited

LMDXWNASDAQ
Healthcare
Medical - Diagnostics & Research
$0.004
$0.00(0.00%)
U.S. Market opens in 15h 40m

LumiraDx Limited Fundamental Analysis

LumiraDx Limited (LMDXW) shows weak financial fundamentals with a PE ratio of -0.01, profit margin of -1.77%, and ROE of -15.58%. The company generates $1.1B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position8642.47%
PEG Ratio-0.00
Current Ratio2.91

Areas of Concern

ROE-15.58%
Operating Margin-1.26%
We analyze LMDXW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -2028.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-2028.7/100

We analyze LMDXW's fundamental strength across five key dimensions:

Efficiency Score

Weak

LMDXW struggles to generate sufficient returns from assets.

ROA > 10%
-1.02%

Valuation Score

Excellent

LMDXW trades at attractive valuation levels.

PE < 25
-0.01
PEG Ratio < 2
-0.00

Growth Score

Weak

LMDXW faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

LMDXW maintains a strong and stable balance sheet.

Debt/Equity < 1
-3.82
Current Ratio > 1
2.91

Profitability Score

Weak

LMDXW struggles to sustain strong margins.

ROE > 15%
-1557.76%
Net Margin ≥ 15%
-1.77%
Positive Free Cash Flow
No

Key Financial Metrics

Is LMDXW Expensive or Cheap?

P/E Ratio

LMDXW trades at -0.01 times earnings. This suggests potential undervaluation.

-0.01

PEG Ratio

When adjusting for growth, LMDXW's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values LumiraDx Limited at -0.04 times its book value. This may indicate undervaluation.

-0.04

EV/EBITDA

Enterprise value stands at 1.08 times EBITDA. This is generally considered low.

1.08

How Well Does LMDXW Make Money?

Net Profit Margin

For every $100 in sales, LumiraDx Limited keeps $-1.77 as profit after all expenses.

-1.77%

Operating Margin

Core operations generate -1.26 in profit for every $100 in revenue, before interest and taxes.

-1.26%

ROE

Management delivers $-15.58 in profit for every $100 of shareholder equity.

-15.58%

ROA

LumiraDx Limited generates $-1.02 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.02%

Following the Money - Real Cash Generation

Operating Cash Flow

LumiraDx Limited generates limited operating cash flow of $-714.74M, signaling weaker underlying cash strength.

$-714.74M

Free Cash Flow

LumiraDx Limited generates weak or negative free cash flow of $-824.89M, restricting financial flexibility.

$-824.89M

FCF Per Share

Each share generates $-0.66 in free cash annually.

$-0.66

FCF Yield

LMDXW converts -36.67% of its market value into free cash.

-36.67%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.01

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.04

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.02

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-3.82

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.91

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-15.58

vs 25 benchmark

ROA

Return on assets percentage

-1.02

vs 25 benchmark

ROCE

Return on capital employed

-0.92

vs 25 benchmark

How LMDXW Stacks Against Its Sector Peers

MetricLMDXW ValueSector AveragePerformance
P/E Ratio-0.0129.43 Better (Cheaper)
ROE-1557.76%800.00% Weak
Net Margin-176.52%-20145.00% (disorted) Weak
Debt/Equity-3.820.30 Strong (Low Leverage)
Current Ratio2.914.64 Strong Liquidity
ROA-101.86%-17936.00% (disorted) Weak

LMDXW outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews LumiraDx Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ